MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $74.43 Average PT from Analysts

Key Points

• MoonLake Immunotherapeutics has received a consensus rating of "Moderate Buy" from nine research firms, with a target price averaging $74.43.
• The company's stock increased by 5.8% recently, with a current market cap of $3.48 billion and a twelve-month price range between $31.42 and $61.87.
• MoonLake Immunotherapeutics reported a loss of ($0.87) earnings per share in its latest earnings, falling short of the estimated ($0.73) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has received an average rating of "Moderate Buy" from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $74.4286.

A number of research analysts have recently weighed in on MLTX shares. Redburn Atlantic raised MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. The Goldman Sachs Group increased their price objective on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Rothschild & Co Redburn started coverage on MoonLake Immunotherapeutics in a report on Monday, July 28th. They issued a "neutral" rating and a $65.00 price objective on the stock. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $67.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd.

MoonLake Immunotherapeutics Stock Down 0.7%

MoonLake Immunotherapeutics stock traded down $0.38 during midday trading on Friday, reaching $53.78. The company's stock had a trading volume of 649,035 shares, compared to its average volume of 740,562. The stock's 50-day simple moving average is $54.29 and its 200-day simple moving average is $45.53. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65. MoonLake Immunotherapeutics has a 52-week low of $31.42 and a 52-week high of $61.87. The stock has a market capitalization of $3.45 billion, a P/E ratio of -19.35 and a beta of 1.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same quarter in the prior year, the firm posted ($0.39) earnings per share. On average, sell-side analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MLTX. Zimmer Partners LP acquired a new stake in MoonLake Immunotherapeutics during the first quarter worth about $957,000. Caxton Associates LLP acquired a new stake in MoonLake Immunotherapeutics during the first quarter worth about $347,000. Octagon Capital Advisors LP acquired a new stake in MoonLake Immunotherapeutics during the first quarter worth about $11,565,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in MoonLake Immunotherapeutics by 17.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company's stock worth $2,287,000 after acquiring an additional 6,422 shares during the period. Finally, Granahan Investment Management LLC grew its holdings in MoonLake Immunotherapeutics by 4.2% during the first quarter. Granahan Investment Management LLC now owns 142,220 shares of the company's stock worth $5,557,000 after acquiring an additional 5,782 shares during the period. 93.85% of the stock is owned by institutional investors and hedge funds.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.